# Gain Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gain-therapeutics

- Industry: Biotechnology
- Headquarters: Bethesda, US
- Website: www.gaintherapeutics.com
- Total disclosed funding: $13M
- Latest round: Series B (Jul 20, 2020)
- Investors on record: 4

## About

Gain Therapeutics, Inc. is a biotechnology company focused on developing next-generation allosteric small molecule therapies to address neurodegenerative disorders, including Parkinson’s disease, utilizing their proprietary Magellan™ platform.Founded in 2017 and headquartered in Bethesda, US, Gain Therapeutics is dedicated to advancing therapies for neurodegenerative diseases. The company has not reported any significant changes in its business strategy or operations since its inception. Lorenzo Leoni, the founder, has a history in biotechnology, while Matthias Alder serves as the CEO. Gain Therapeutics has successfully completed 4 deals, with its latest funding being an IPO in March 2021, where it raised USD 40 mn.Gain Therapeutics develops innovative therapies targeting GBA-Parkinson’s disease and other neurodegenerative disorders. Their lead candidate, GT-02287, is in a Phase I clinical trial and aims to modulate protein functions using their AI-supported Magellan™ platform. The therapies are designed for patients with neurodegenerative conditions, and the firm collaborates with healthcare providers and pharmaceutical partners for development and commercialization.In the most recent fiscal year of 2023, Gain Therapeutics reported revenues of USD 55,180, with an EBITDA loss of USD 22,169,554, primarily generated from partnerships and collaborations with pharmaceutical companies for drug development and commercialization.Gain Therapeutics plans to utilize the USD 40 mn raised in its IPO to complete IND-enabling studies for its two lead development programs and advance additional pipeline candidates. The company aims to expand into North American and European markets, focusing on providing advanced treatments for neurodegenerative diseases, aligning with their strategy for growth through innovation and collaboration.

## Funding rounds

- Series B, Jul 20, 2020, $10M — Allele Capital Partners
- Series A, Feb 19, 2019, $2.8M — 3B Future Health Fund, TiVenture, VitaTech S.A.

## Investors

- 3B Future Health Fund (https://capitalatlas.ai/funds/3b-future-health-fund) — Series A
- TiVenture (https://capitalatlas.ai/funds/tiventure) — Series A
- VitaTech S.A. — Series A
- Allele Capital Partners (https://capitalatlas.ai/funds/allele-capital-partners) — Series B